المؤلفون: Anton K. Peresada, David P. Dundua, Anna G. Kedrova, Irina N. Oleinikova, Alisa V. Salimova

المصدر: Клиническая практика, Vol 15, Iss 3, Pp 7-16 (2024)

مصطلحات موضوعية: cardio-oncology, cardiotoxicity, cardioprotection, chronic heart failure, sodium-glucose cotransporter type 2 inhibitors, Medicine

وصف الملف: electronic resource

Relation: https://journals.eco-vector.com/clinpractice/article/viewFile/629938/pdf; https://doaj.org/toc/2220-3095; https://doaj.org/toc/2618-8627

URL الوصول: https://doaj.org/article/3ab7bcd7b17543a7863c274930ab080a

المؤلفون: Dejana Rakic, Vladimir Jakovljevic, Vladimir Zivkovic, Jovana Jakovljevic Uzelac, Nikola Jovic, Maja Muric, Bozidar Pindovic, Aleksandra Dimitrijevic, Petar Arsenijevic, Jovan Rakic, Slobodanka Mitrovic, Tatjana Vulovic, Jovana Joksimovic Jovic

المصدر: Pathophysiology, Vol 31, Iss 4, Pp 559-582 (2024)

مصطلحات موضوعية: polycystic ovary syndrome, metformin, empagliflozin, rats, sodium-glucose cotransporter type 2 inhibitors, metabolic syndrome, Physiology, QP1-981

وصف الملف: electronic resource

Relation: https://www.mdpi.com/1873-149X/31/4/41; https://doaj.org/toc/1873-149X

URL الوصول: https://doaj.org/article/0b9e1b07b0094e328d104e33116b821f

المؤلفون: Abed Alharbi, Samar, Alsubaiei, Amal Ahmad, Alkhalifah, Ali Hussain, Alshehri, Abdulrahman Abdulaziz, Alhaggas, Shoog Soliman, Alhuthli, Shahad Marwan, Alfaqih, Yousef Hassan, Alnajjar, Wed Ziyad, Alshaban, Ghaida Abdulla, Ahmed, Mahmood Sameer, Alqarni, Abdulkarem Sarhan

المصدر: International Journal Of Community Medicine And Public Health; In Press ; 2394-6040 ; 2394-6032

مصطلحات موضوعية: Sodium-glucose cotransporter type 2 inhibitors, SGLT2 inhibitors, Gliflozins, Cardiovascular health, Cardioprotective effects, Empagliflozin, Dapagliflozin

وصف الملف: application/pdf

Relation: https://www.ijcmph.com/index.php/ijcmph/article/view/13644/8123; https://www.ijcmph.com/index.php/ijcmph/article/view/13644

الاتاحة: https://www.ijcmph.com/index.php/ijcmph/article/view/13644
https://doi.org/10.18203/2394-6040.ijcmph20250050

المؤلفون: Andrey N. Surkov, Leyla S. Namazova-Baranova, Anna L. Arakelyan, Evgeny E. Bessonov, Natalia V. Zhurkova

المصدر: Вопросы современной педиатрии, Vol 23, Iss 3, Pp 162-167 (2024)

مصطلحات موضوعية: glycogen storage disease type ib, neutropenia, granulocyte colony-stimulating factor, sodium-glucose cotransporter type 2 inhibitors, gliflozins, Pediatrics, RJ1-570

وصف الملف: electronic resource

Relation: https://vsp.spr-journal.ru/jour/article/view/3521; https://doaj.org/toc/1682-5527; https://doaj.org/toc/1682-5535

URL الوصول: https://doaj.org/article/8b4ab6f90c7b4f8b855be3182c18ab2f

المؤلفون: Oksana V. Tsygankova, Olga V. Timoshchenko, Natalia E. Apartseva, Liudmila D. Latyntseva

المصدر: Терапевтический архив, Vol 96, Iss 4, Pp 364-369 (2024)

مصطلحات موضوعية: recurrent cystitis, women, type 2 diabetes mellitus, phytouroseptics, sodium-glucose cotransporter type 2 inhibitors, gliflosins, canephron® n, phytotherapy, Medicine

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/viewFile/631531/146941; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/758b3f9958f54c1892cd2a0fb228a338

المؤلفون: Anton K. Peresada, David P. Dundua, Anna G. Kedrova, Irina N. Oleynikova, Anna V. Masterkova

المصدر: Клиническая практика, Vol 14, Iss 4, Pp 75-87 (2024)

مصطلحات موضوعية: cardio-oncology, cardiotoxicity, cardioprotection, chronic heart failure, sodium-glucose cotransporter type 2 inhibitors, Medicine

وصف الملف: electronic resource

Relation: https://journals.eco-vector.com/clinpractice/article/viewFile/567924/pdf; https://doaj.org/toc/2220-3095; https://doaj.org/toc/2618-8627

URL الوصول: https://doaj.org/article/496cfc8fff864dac977f1a57afd576a8

المؤلفون: Oksana V. Tsygankova, Natalia E. Evdokimova, Olga V. Timoshchenko, Lydmila D. Latyntseva

المصدر: Терапевтический архив, Vol 95, Iss 8, Pp 664-669 (2023)

مصطلحات موضوعية: recurrent cystitis, urinary tract infection, type 2 diabetes mellitus, phytotherapy, sodium-glucose cotransporter type 2 inhibitors, canephron® n, Medicine

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/viewFile/607413/136055; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/6a34022af4954e1b86f715a81b68bf64

المؤلفون: Anton K. Peresada, Nikolay V. Dupik, David P. Dundua, Anna G. Kedrova, Sergey V. Korolev, Roman S. Chaikin

المصدر: Клиническая практика, Vol 14, Iss 2, Pp 96-104 (2023)

مصطلحات موضوعية: cardio-oncology, cardiotoxicity, quadrotherapy of chronic heart failure, sodium-glucose cotransporter type 2 inhibitors, catheter ablation of ventricular arrhythmia, Medicine

وصف الملف: electronic resource

Relation: https://journals.eco-vector.com/clinpractice/article/viewFile/202813/pdf; https://doaj.org/toc/2220-3095; https://doaj.org/toc/2618-8627

URL الوصول: https://doaj.org/article/dfdb312c48214b52bc50666ee06dd555

المؤلفون: Оksana S. Fuks, Anna V. Simanenkova, Natalya V. Timkina, Polina A. Tikhomirova, Aleksandr Z. Gagiev, Tatiana L. Karonova

المصدر: Consilium Medicum, Vol 25, Iss 4, Pp 247-252 (2023)

مصطلحات موضوعية: diabetes mellitus, chronic brain dyscirculation, neuroprotection, sodium glucose cotransporter type 2 inhibitors, empagliflozin, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://consilium.orscience.ru/2075-1753/article/viewFile/568232/133639; https://doaj.org/toc/2075-1753; https://doaj.org/toc/2542-2170

URL الوصول: https://doaj.org/article/b596231d4aa14a53847873e3b9bdac21

المؤلفون: Michele Correale, Elena‐Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans‐Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Javed Butler, Savina Nodari, Master Program Group on Drug Development for Heart Failure

المصدر: ESC Heart Failure, Vol 10, Iss 3, Pp 2066-2073 (2023)

مصطلحات موضوعية: Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i), Heart failure (HF), Cardiac structure and function, Echocardiography, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2055-5822

URL الوصول: https://doaj.org/article/de59c9a117ce41d4beb61fc436b157b3

المؤلفون: Yu. S. Ignatova, S. U. Shuster, T. B. Pecherina, O. L. Barbarash

المصدر: Российский кардиологический журнал, Vol 29, Iss 1 (2024)

مصطلحات موضوعية: sodium-glucose cotransporter type 2 inhibitors, heart failure, myocardial fibrosis, prognosis, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://russjcardiol.elpub.ru/jour/article/view/5580; https://doaj.org/toc/1560-4071; https://doaj.org/toc/2618-7620

URL الوصول: https://doaj.org/article/127a3ac1e24f41db8ea499539167309a

المؤلفون: Cortés, Marcelino, Lorenzo González, Óscar, Lumpuy Castillo, Jairo, Martínez Albaladejo, Sacramento, Taibo Urquía, Mikel, María Pello, Ana, Bollas, Antonio José, Orejas, Miguel, Navas, Miguel Ángel, Macia, Ester, Martínez, María Esther, Rueda, Andrea, Tuñón Fernández, José Luis

المساهمون: UAM. Departamento de Medicina

مصطلحات موضوعية: sodium-glucose cotransporter type 2 inhibitors, dapagliflozin, speckle tracking, biomarkers, echocardiography, Medicina

وصف الملف: application/pdf

Relation: Journal of Clinical Medicine; https://doi.org/10.3390/jcm12206698; Gobierno de España. PI20/00923; http://hdl.handle.net/10486/716418; 20; 12

الاتاحة: http://hdl.handle.net/10486/716418
https://doi.org/10.3390/jcm12206698

المؤلفون: O. M. Koteshkova, M. B. Antsiferov, D. M. Antsiferova, Yu. V. Golubeva, N. A. Demidov, О. И. Котешкова, М. Б. Анциферов, Д. М. Анциферова, Ю. В. Голубева, Н. А. Демидов

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 64-71 ; Медицинский Совет; № 6 (2024); 64-71 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: стандарты исследования, CPAP therapy, sodium-glucose cotransporter type 2 inhibitors, dapagliflozin, research standards, СИПАП-терапия, ингибиторы натрий-глюкозного котранспортера 2-го типа, дапаглифлозин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8271/7293; Cowie MR, Linz D, Redline S, Somers VK, Simonds AK. Sleep Disordered Breathing and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(6):608–624. https://doi.org/10.1016/j.jacc.2021.05.048.; Javaheri S, Peker Y, Yaggi HK, Bassetti CLA. Obstructive sleep apnea and stroke: The mechanisms, the randomized trials, and the road ahead. Sleep Med Rev. 2022;61:101568. https://doi.org/10.1016/j.smrv.2021.101568.; Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687–698. https://doi.org/10.1016/S2213-2600(19)30198-5.; Wang T, Yu FC, Wei Q, Chen L, Xu X, Ding N, Tong JY. Prevalence and clinical characteristics of sleep-disordered breathing in patients with heart failure of different left ventricular ejection fractions. Sleep Breath. 2023;27(1):245–253. https://doi.org/10.1007/s11325-022-02611-4.; Abdullah A, Eigbire G, Salama A, Wahab A, Nadkarni N, Alweis R. Relation of Obstructive Sleep Apnea to Risk of Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction from the National Inpatient Sample. Am J Cardiol. 2018;122(4):612–615. https://doi.org/10.1016/j.amjcard.2018.04.052.; Oldenburg O, Wellmann B, Buchholz A, Bitter T, Fox H, Thiem U et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. Eur Heart J. 2016;37(21):1695–1703. https://doi.org/10.1093/eurheartj/ehv624.; Veasey SC, Rosen IM. Obstructive Sleep Apnea in Adults. N Engl J Med. 2019;380(15):1442–1449. https://doi.org/10.1056/NEJMcp1816152.; Reutrakul S, Mokhlesi B. Obstructive Sleep Apnea and Diabetes: A State of the Art Review. Chest. 2017;152(5):1070–1086. https://doi.org/10.1016/j.chest.2017.05.009.; Seicean S, Strohl KP, Seicean A, Gibby C, Marwick TH. Sleep disordered breathing as a risk of cardiac events in subjects with diabetes mellitus and normal exercise echocardiographic findings. Am J Cardiol. 2013;111(8):1214–1220. https://doi.org/10.1016/j.amjcard.2012.12.053.; Butt JH, Jering K, De Boer RA, Claggett BL, Desai AS, Hernandez AF et al. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. J Card Fail. 2024;30(3):436–448. https://doi.org/10.1016/j.cardfail.2023.08.027.; Edmonds PJ, Gunasekaran K, Edmonds LC. Neck Grasp Predicts Obstructive Sleep Apnea in Type 2 Diabetes Mellitus. Sleep Disord. 2019:3184382. https://doi.org/10.1155/2019/3184382.; Kristensen SL, Jhund PS, Lee MMY, Køber L, Solomon SD, Granger CB et al. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther. 2017;31(5-6):545–549. https://doi.org/10.1007/s10557-017-6754-x.; Дедов ИИ, Шестакова МВ, Майоров АЮ (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 11-й вып. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042.; White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. J Physiol. 2013;591(5):1179–1193. https://doi.org/10.1113/jphysiol.2012.245159.; Cowie MR. Sleep-Disordered Breathing – Do We Have to Change Gears in Heart Failure? Curr Heart Fail Rep. 2016;13(5):255–265. https://doi.org/10.1007/s11897-016-0304-x.; Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation. 2005;112(17):2660–2667. https://doi.org/10.1161/CIRCULATIONAHA.105.556746.; Beck MK, Westergaard D, Jensen AB, Groop L, Brunak S. Temporal order of disease pairs affects subsequent disease trajectories: the case of diabetes and sleep apnea. Pac Symp Biocomput. 2017;22:380–389. https://doi.org/10.1142/9789813207813_0036.; Adderley NJ, Subramanian A, Toulis K, Gokhale K, Taverner T, Hanif W et al. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study. Diabetes Care. 2020;43(8):1868–1877. https://doi.org/10.2337/dc19-2116.; Shi H, Jiang X. Correlation Between QTc Prolongation and Obstructive Sleep Apnea in Patients with Type 2 Diabetes Mellitus. Med Sci Monit. 2020;26:e926954. https://doi.org/10.12659/MSM.926954.; Shamsuzzaman A, Amin RS, van der Walt C, Davison DE, Okcay A, Pressman GS, Somers VK. Daytime cardiac repolarization in patients with obstructive sleep apnea. Sleep Breath. 2015;19(4):1135–1140. https://doi.org/10.1007/s11325-015-1119-9.; Strausz S, Havulinna AS, Tuomi T, Bachour A, Groop L, Mäkitie A et al. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open. 2018;8(10):e022752. https://doi.org/10.1136/bmjopen-2018-022752.; Su X, Li JH, Gao Y, Chen K, Gao Y, Guo JJ et al. Impact of obstructive sleep apnea complicated with type 2 diabetes on long-term cardiovascular risks and all-cause mortality in elderly patients. BMC Geriatr. 2021;21(1):508. https://doi.org/10.1186/s12877-021-02461-x.; Labarca G, Dreyse J, Salas C, Schmidt A, Rivera F, Letelier F, Jorquera J. Risk of mortality among patients with moderate to severe obstructive sleep apnea and diabetes mellitus: results from the SantOSA cohort. Sleep Breath. 2021;25(3):1467–1475. https://doi.org/10.1007/s11325-020-02283-y.; Wang X, Fan J, Du Y, Ma C, Ma X, Nie S, Wei Y. Clinical significance of obstructive sleep apnea in patients with acute coronary syndrome in relation to diabetes status. BMJ Open Diabetes Res Care. 2019;7(1):e000737. https://doi.org/10.1136/bmjdrc-2019-000737.; Koo CY, Drager LF, Sethi R, Ho HH, Hein T, Jim MH et al. Obstructive Sleep Apnea and Diabetes Independently Add to Cardiovascular Risk After Coronary Revascularization. Diabetes Care. 2018;41(2):e12–e14. https://doi.org/10.2337/dc17-0759.; Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP et al. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus: Insights From the PROSPECT Study. JACC Cardiovasc Imaging. 2017;10(4):451–458. https://doi.org/10.1016/j.jcmg.2015.12.023.; Wang H, Li X, Tang Z, Gong G. Cardiovascular Outcomes Post Percutaneous Coronary Intervention in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther. 2020;11(8):1795–1806. https://doi.org/10.1007/s13300-020-00870-6.; Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Launois S, Borel AL, Levy P, Pepin JL. Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a systematic review from sham CPAP randomized controlled trials. Sleep Med Rev. 2015;21:23–38. https://doi.org/10.1016/j.smrv.2014.07.004.; Farías JG, Herrera EA, Carrasco-Pozo C, Sotomayor-Zárate R, Cruz G, Morales P, Castillo RL. Pharmacological models and approaches for pathophysiological conditions associated with hypoxia and oxidative stress. Pharmacol Ther. 2016;158:1–23. https://doi.org/10.1016/j.pharmthera.2015.11.006.; Zhang R, Zhang P, Zhao F, Han X, Ji L. Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes. Diabetes Technol Ther. 2016;18(7):415–420. https://doi.org/10.1089/dia.2015.0433.; Siwasaranond N, Nimitphong H, Manodpitipong A, Saetung S, Chirakalwasan N, Thakkinstian A, Reutrakul S. The Relationship between Diabetes-Related Complications and Obstructive Sleep Apnea in Type 2 Diabetes. J Diabetes Res. 2018:9269170. https://doi.org/10.1155/2018/9269170.; Huang T, Lin BM, Stampfer MJ, Tworoger SS, Hu FB, Redline S. A PopulationBased Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. Diabetes Care. 2018;41(10):2111–2119. https://doi.org/10.2337/dc18-0675.; Jehan S, Myers AK, Zizi F, Pandi-Perumal SR, Jean-Louis G, McFarlane SI. Obesity, obstructive sleep apnea and type 2 diabetes mellitus: Epidemiology and pathophysiologic insights. Sleep Med Disord. 2018;2(3):52–58. https://doi.org/10.15406/smdij.2018.02.00045.; Triantafyllou GA, Paschou SA, Mantzoros CS. Leptin and Hormones: Energy Homeostasis. Endocrinol Metab Clin North Am. 2016;45(3):633–645. https://doi.org/10.1016/j.ecl.2016.04.012.; Imayama I, Prasad B. Role of Leptin in Obstructive Sleep Apnea. Ann Am Thorac Soc. 2017;14(11):1607–1621. https://doi.org/10.1513/AnnalsATS.201702-181FR.; Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479–504. https://doi.org/10.5664/jcsm.6506.; Malhotra A, Ayappa I, Ayas N, Collop N, Kirsch D, Mcardle N et al. Metrics of sleep apnea severity: beyond the apnea-hypopnea index. Sleep. 2021;44(7):zsab030. https://doi.org/10.1093/sleep/zsab030.; Abrams B. Comment on: use of blood biomarkers to screen for obstructive sleep apnea. Nat Sci Sleep. 2018;10:313–315. https://doi.org/10.2147/NSS.S179670.; Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2017;318(2):156–166. https://doi.org/10.1001/jama.2017.7967.; Bakker JP, Weaver TE, Parthasarathy S, Aloia MS. Adherence to CPAP: What Should We Be Aiming For, and How Can We Get There? Chest. 2019;155(6):1272–1287. https://doi.org/10.1016/j.chest.2019.01.012.; Loffler KA, Heeley E, Freed R, Meng R, Bittencourt LR, Gonzaga Carvalho CC et al. Continuous Positive Airway Pressure Treatment, Glycemia, and Diabetes Risk in Obstructive Sleep Apnea and Comorbid Cardiovascular Disease. Diabetes Care. 2020;43(8):1859–1867. https://doi.org/10.2337/dc19-2006.; Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stampouloglou PK et al. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. J Diabetes Res. 2018:1232583. https://doi.org/10.1155/2018/1232583.; Siasos G, Stampouloglou PK, Bletsa E, Paschou SA, Oikonomou E, Giannopoulos G et al. SGLT-2i and Cardiovascular Prognosis. Curr Pharm Des. 2020;26(32):3905–3907. https://doi.org/10.2174/138161282632200811172751.; Siasos G, Bletsa E, Stampouloglou PK, Paschou SA, Oikonomou E, Tsigkou V et al. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Curr Pharm Des. 2020;26(46):5911–5932. https://doi.org/10.2174/1381612826666201109110107.; Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020;43(12):3007–3015. https://doi.org/10.2337/dc20-1096.; Hudgel DW. Critical review: CPAP and weight management of obstructive sleep apnea cardiovascular co-morbidities. Sleep Med Rev. 2018;37:14–23. https://doi.org/10.1016/j.smrv.2016.12.001.; Hudgel DW, Patel SR, Ahasic AM, Bartlett SJ, Bessesen DH, Coaker MA et al. The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(6):e70–e87. https://doi.org/10.1164/rccm.201807-1326ST.; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.; Randerath W, Verbraecken J, Andreas S, Arzt M, Bloch KE, Brack T et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017;49(1):1600959. https://doi.org/10.1183/13993003.00959-2016.; Tang Y, Sun Q, Bai XY, Zhou YF, Zhou QL, Zhang M. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutr Diabetes. 2019;9(1):32. https://doi.org/10.1038/s41387-019-0098-5.; Jaffuel D, Bouchaut Y, Mallet JP, Vidal C, Molinari N, Bourdin A, Roubille F. Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea. ERJ Open Res. 2023;9(3):00123-2023. https://doi.org/10.1183/23120541.00123-2023.; Furukawa S, Miyake T, Senba H, Sakai T, Furukawa E, Yamamoto S et al. The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus. Endocr J. 2018;65(9):953–961. https://doi.org/10.1507/endocrj.EJ17-0545.; https://www.med-sovet.pro/jour/article/view/8271

الاتاحة: https://www.med-sovet.pro/jour/article/view/8271
https://doi.org/10.21518/ms2024-179

المؤلفون: V. N. Larina, M. V. Leonova, В. Н. Ларина, М. В. Леонова

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 187-196 ; Медицинский Совет; № 6 (2024); 187-196 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: прогноз, left ventricular ejection fraction, sodium-glucose cotransporter type 2 inhibitors, quadruple therapy, prognosis, фракция выброса левого желудочка, ингибиторы натрий-глюкозного котранспортера-2, квадротерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8284/7305; Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. https://doi.org/10.1093/cvr/cvac013.; Шляхто ЕВ, Беленков ЮН, Бойцов СА, Виллевальде СВ, Галявич АС, Глезер МГ и др. Проспективное наблюдательное многоцентровое регистровое исследование пациентов с хронической сердечной недостаточностью в Российской Федерации (ПРИОРИТЕТ-ХСН): обоснование, цели и дизайн исследования. Российский кардиологический журнал. 2023;28(6):5456. https://doi.org/10.15829/1560-4071-2023-5456.; Gomez-Soto FM, Andrey JL, Garcia-Egido AA, Escobar MA, Romero SP, Garcia-Arjona R et al. Incidence and mortality of heart failure: a communitybased study. Int J Cardiol. 2011;151:40–45. https://doi.org/10.1016/j.ijcard.2010.04.055.; Шляхто ЕВ, Беленков ЮН, Бойцов СА, Виллевальде СВ, Галявич АС, Глезер МГ и др. Результаты промежуточного анализа проспективного наблюдательного многоцентрового регистрового исследования пациентов с хронической сердечной недостаточностью в Российской Федерации «ПРИОРИТЕТ-ХСН»: исходные характеристики и лечение первых включенных пациентов. Российский кардиологический журнал. 2023;28(10):5593. https://doi.org/10.15829/1560-4071-2023-5593.; Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816.; Gutmann C, Zelniker T, Mayr M. SGLT2 inhibitors in heart failure: insights from plasma proteomics. Eur Heart J. 2022;43(48):5003–5005. https://doi.org/10.1093/eurheartj/ehac624.; Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium– glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422–434. https://doi.org/10.1016/J.JACC.2019.11.031.; Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632–644. https://doi.org/10.1016/j.jacbts.2020.02.004.; Dardano A, Miccoli R, Bianchi C, Daniele G, Del Prato S. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: which patients for GLP-1RA or SGLT-2 inhibitor? Diabetes Res Clin Pract. 2020;162:108112. https://doi.org/10.1016/j.diabres.2020.108112.; Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci. 2022;23(7):3587. https://doi.org/10.3390/ijms23073587.; Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117(1):74–84. https://doi.org/10.1093/cvr/cvaa064.; Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197. https://doi.org/10.1371/journal.pmed.0050197.; Паневин ТС, Елисеев МС, Бобкова АО, Димитрева АЕ, Урумова ММ. Применение дапаглифлозина у коморбидного пациента: новые возможности. Нефрология. 2023;27(2):109–115. https://doi.org/10.36485/1561-6274-2023-27-2-109-115.; Pandey AK, Bhatt DL, Pandey A, Marx N, Cosentino F, Pandey A, Verma S. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640–3651. https://doi.org/10.1093/eurheartj/ehad389.; Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028–1039. https://doi.org/10.1161/CIRCULATIONAHA.120.045691.; Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.; McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303.; Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720.; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128.; Мареев ВЮ, Фомин ИВ, Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017;18(1):3–40. Режим доступа: https://endovascular-society.ru/download/guidelines_2/2016_CHF_rus.pdf.; Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. Available at: https://pubmed.ncbi.nlm.nih.gov/30415602.; Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205–2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.; Marx N, Müller-Wieland D. SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world. Eur Heart J. 2023;44(24):2231–2233. https://doi.org/10.1093/eurheartj/ehad282.; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.; Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Бойцов СА, Васюк ЮА и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083.; Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757–767. https://doi.org/10.1016/S0140-6736(22)01429-5.; Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R et al. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. Eur Heart J. 2023;44(24):2216–2230. https://doi.org/10.1093/eurheartj/ehad273.; Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038.; Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. https://doi.org/10.1016/S0140-6736(20)31824-9.; Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;32:100690. https://doi.org/10.1016/j.ijcha.2020.100690.; Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C et al. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther. 2021;35(5):1067–1076. https://doi.org/10.1007/s10557-020-07099-2.; Ahmad Y, Madhavan MV, Stone GW, Francis DP, Makkar R, Bhatt DL, Howard JP. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):383–390. https://doi.org/10.1093/ehjqcco/qcab072.; Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–155. https://doi.org/10.1002/clc.23321.; Zhou Q, Li P, Zhao H, Xu X, Li S, Zhao J et al. Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. Front Cardiovasc Med. 2021;8:678121. https://doi.org/10.3389/fcvm.2021.678121.; Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43(5):416–426. https://doi.org/10.1093/eurheartj/ehab798.; Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286.; Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117–128. https://doi.org/10.1056/NEJMoa2030183.; Banerjee M, Pal R, Nair K, Mukhopadhyay S. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart J. 2023;75(2):122–127. https://doi.org/10.1016/j.ihj.2023.03.003.; Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129–139. https://doi.org/10.1056/NEJMoa2030186.; Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130.; Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967.; Xiang B, Zhang R, Wu X, Zhou X. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Metaanalysis. JAMA Netw Open. 2022;5(9):e2231963. https://doi.org/10.1001/jamanetworkopen.2022.31963.; Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23(1):2. https://doi.org/10.1186/s12933-023-02042-9.; Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? JACC Basic Transl Sci. 2022;7(5):504–517. https://doi.org/10.1016/j.jacbts.2021.10.018.; Голухова ЕЗ. Эксперты призывают незамедлительно начинать четырехкомпонентную терапию больным с сердечной недостаточностью и сниженной фракцией выброса левого желудочка. Креативная кардиология. 2020;14(3):201–205. https://doi.org/10.24022/1997-3187-2020-14-3-201-205.; Карпов ЮА, Пушкарева СЮ, Тхорикова ВН. «Великолепная четверка»: эффективность и влияние каждого из 4 компонентов базовой терапии и своевременности их назначения на прогноз пациентов с хронической сердечной недостаточностью. Новости кардиологии. 2022;(1):32–40. https://doi.org/10.24412/2076-4189-2022-12702.; Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive diseasemodifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128. https://doi.org/10.1016/S0140-6736(20)30748-0.; Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73–84. https://doi.org/10.1016/j.jchf.2021.09.004.; Xiang B, Yu Z, Zhou X. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Front Cardiovasc Med. 2022;8:787810. https://doi.org/10.3389/fcvm.2021.787810.; Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022.; McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37(4):531–546. https://doi.org/10.1016/j.cjca.2021.01.017.; Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL et al. Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure. Eur J Heart Fail. 2023;25(7):999–1009. https://doi.org/10.1002/ejhf.2864.; https://www.med-sovet.pro/jour/article/view/8284

الاتاحة: https://www.med-sovet.pro/jour/article/view/8284
https://doi.org/10.21518/ms2024-129

المؤلفون: Inês Henriques Vieira, Tânia Santos Carvalho, Joana Saraiva, Leonor Gomes, Isabel Paiva

المصدر: Biomedicines, Vol 12, Iss 5, p 1102 (2024)

مصطلحات موضوعية: stroke, diabetes type 2, glucagon-like peptide 1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors, Biology (General), QH301-705.5

Relation: https://www.mdpi.com/2227-9059/12/5/1102; https://doaj.org/toc/2227-9059; https://doaj.org/article/09f208d55dc34b4ea838243b56369a48

الاتاحة: https://doi.org/10.3390/biomedicines12051102
https://doaj.org/article/09f208d55dc34b4ea838243b56369a48

المؤلفون: Emma S. Speedtsberg, Martin Tepel

المصدر: Frontiers in Endocrinology, Vol 14 (2023)

مصطلحات موضوعية: diabetic chronic kidney disease, nondiabetic chronic kidney disease, sodium glucose cotransporter type 2 inhibitors, nephroprotection, pathophysiologic mechanisms, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2023.1281107/full; https://doaj.org/toc/1664-2392

URL الوصول: https://doaj.org/article/32ba1bc7c0624eac89059bfb0cce62c8

المؤلفون: Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

المصدر: Drugs in Context, Vol 12, Pp 1-14 (2023)

مصطلحات موضوعية: angiotensin ii receptor-neprilysin inhibitor, arni, dapagliflozin, empagliflozin, heart failure, mineralocorticoid receptor antagonists, mra, sacubitril/valsartan, sodium–glucose cotransporter type 2 inhibitors, sglt2i, sodium–glucose cotransporter 2 inhibitors, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://drugsincontext.com/emerging-concepts-in-heart-failure-management-and-treatment-focus-on-current-guideline-directed-medical-therapy-for-heart-failure-with-reduced-ejection-fraction; https://doaj.org/toc/1740-4398

URL الوصول: https://doaj.org/article/8fa3981eb38a4f5fbdb6d8e2c7116d50

المؤلفون: Fulvio Cacciapuoti, Antonio D'Onofrio, Luca Gaetano Tarquinio, Valentina Capone, Ciro Mauro, Raffaele Marfella, Federico Cacciapuoti

المصدر: Monaldi Archives for Chest Disease (2023)

مصطلحات موضوعية: heart failure, sleep-disordered breathing, sleep apnea syndrome, sodium-glucose cotransporter type 2 inhibitors, Medicine

وصف الملف: electronic resource

Relation: https://www.monaldi-archives.org/index.php/macd/article/view/2660; https://doaj.org/toc/1122-0643; https://doaj.org/toc/2532-5264

URL الوصول: https://doaj.org/article/b2b347e81f7947fca91d37e439da2e42

المؤلفون: Ahmed Hassoun, Denish Kumar Dhanwal, Jalal Nafach, Yasmin Ajaz, Asif Majid Khan, Abdullah Ben Nakhi, Monira AlArouj, Khadija Hafidh, Majdi AlNajjar, Ahmed Reyas, Sana Qamar, Mohamed Alsayed, Ahmad Bdair

المصدر: Dubai Diabetes and Endocrinology Journal, Pp 1-10 (2022)

مصطلحات موضوعية: dapagliflozin, sodium-glucose cotransporter type 2, sodium-glucose cotransporter type 2 inhibitors, diabetes mellitus, type 2 diabetes mellitus, type 2 diabetes, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://www.karger.com/Article/FullText/519871; https://doaj.org/toc/2673-1797; https://doaj.org/toc/2673-1738

URL الوصول: https://doaj.org/article/059bfb4103f2495e97b4cf10defae7cc

المؤلفون: Castillo Moraga, María José, Turégano-Yedro, Miguel, Pallarés-Carratalá, Vicente

مصطلحات موضوعية: Enfermedad Renal Crónica, Diabetes Mellitus, inhibidores del cotransportador sodio-glucosa tipo 2, Chronic Kidney Disease, Sodium-Glucose Cotransporter Type 2 Inhibitors

وصف الملف: application/pdf

Relation: Medicina de Familia. SEMERGEN, 2023, 49: 102020.; CASTILLO MORAGA, María José; TURÉGANO-YEDRO, Miguel; PALLARÉS-CARRATALA, Vicente. Manejo clínico-práctico de los inhibidores del cotransportador sodio-glucosa tipo 2 en pacientes con enfermedad renal crónica. Medicina de Familia. SEMERGEN, 2023, 49: 102020.; http://hdl.handle.net/10234/202965; https://doi.org/10.1016/j.semerg.2023.102020

الاتاحة: http://hdl.handle.net/10234/202965
https://doi.org/10.1016/j.semerg.2023.102020